SAN FRANCISCO | July 9, 2026
Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, has announced a strategic collaboration with Cortechs.ai, a global innovator in quantitative neuroimaging and AI-driven radiology solutions, to expand its platform into the rapidly growing field of neurodegenerative disease management. Through the collaboration, Cortechs.ai’s NeuroQuant® and NeuroQuant® MS technologies will be integrated into the Viz.ai platform, providing hospitals and health systems across the United States with advanced quantitative MRI analysis for multiple sclerosis (MS) and other neurodegenerative disorders. The partnership significantly expands the capabilities of the Viz Neuro Suite, combining AI-powered imaging analytics with real-time clinical workflow coordination to help clinicians identify, monitor, and manage patients more efficiently. By integrating clinically validated neuroimaging intelligence directly into existing care pathways, both companies aim to accelerate diagnosis, improve treatment decisions, and enhance patient outcomes for neurological diseases that continue to present substantial diagnostic and therapeutic challenges worldwide.
AI Collaboration Brings Advanced Neuroimaging to Clinical Workflows
The collaboration represents a major advancement in the application of artificial intelligence for neurological care, bringing together Viz.ai’s intelligent care coordination platform with Cortechs.ai’s FDA-cleared quantitative neuroimaging technologies. The initial focus will center on multiple sclerosis, where NeuroQuant® MS provides automated quantitative MRI analysis capable of measuring brain volume changes and other imaging biomarkers that support earlier disease detection, monitoring, and treatment evaluation.
By embedding these imaging insights directly into Viz.ai’s clinical workflow platform, physicians can access critical imaging data alongside patient information, enabling faster clinical decision-making and improved multidisciplinary collaboration. The integrated solution is expected to simplify care coordination across neurologists, radiologists, and other specialists while reducing delays between imaging interpretation and treatment planning. The collaboration also establishes a scalable framework for expanding AI-supported clinical management into additional neurodegenerative diseases in the future.
Supporting Earlier Detection of Neurodegenerative Diseases
Advertisement
The partnership addresses one of healthcare’s most pressing challenges by improving the identification and management of neurodegenerative diseases, where earlier diagnosis can significantly influence long-term patient outcomes. Multiple sclerosis, Alzheimer’s disease, traumatic brain injury, epilepsy, and other neurological disorders often require highly specialized imaging interpretation combined with continuous disease monitoring. Cortechs.ai’s NeuroQuant® platform, already widely recognized for providing quantitative assessment of brain structures, offers clinicians objective imaging measurements that enhance diagnostic confidence and support personalized treatment planning.
Combined with Viz.ai’s AI-powered care coordination platform, the solution enables healthcare teams to rapidly identify eligible patients, coordinate specialist referrals, and optimize treatment pathways across large hospital networks. With deployment across nearly 2,000 hospitals in the United States, Viz.ai provides one of the healthcare industry’s largest AI-enabled clinical infrastructures, creating significant opportunities to expand access to advanced neuroimaging technologies for patients nationwide.
Expanding AI Innovation Across Neurology and Precision Medicine
The collaboration reflects the continued evolution of artificial intelligence in precision medicine, where integrated digital platforms increasingly combine diagnostic imaging, clinical decision support, and real-time care coordination into unified healthcare ecosystems. Viz.ai, recognized as one of the pioneers in AI-powered clinical workflow automation, continues expanding beyond stroke and acute neurological conditions into broader neurodegenerative disease management, while Cortechs.ai strengthens its position as a leader in quantitative neuroimaging software supporting radiology, neurology, oncology, and clinical research. Company leadership indicated that additional product and partnership announcements focused on neurodegenerative diseases are expected as the platform continues to evolve.
By integrating AI-powered quantitative imaging, clinical workflow automation, and care coordination technologies, the collaboration aims to improve diagnostic accuracy, accelerate treatment decisions, and enhance long-term patient management across multiple neurological conditions. The partnership further demonstrates the growing role of artificial intelligence, advanced medical imaging, and digital health technologies in transforming modern neurological care while supporting hospitals with scalable solutions capable of improving both operational efficiency and patient outcomes.
Source: Viz.ai, Cortechs.ai press release
